Article

Neurometabolite changes in response to antidepressant medication: a systematic review of<sup>1</sup>H-MRS findings

2023-06-18

Abstract excerpt

<h4>ABSTRACT</h4> Selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), and (es-)ketamine are used to treat major depressive disorder (MDD). These different types of medication may involve common neural pathways related to glutamatergic and GABAergic neurotransmitter systems, both of which have been implicated in MDD pathology. We conducted a systematic review of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7d7817d-e7c0-5ffe-bb06-bbca39ed46c6
DOI: 10.1101/2023.06.16.23291487

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neurometabolite changes in response to antidepressant medication: a systematic review of<sup>1</sup>H-MRS findingsDOI 10.1101/2023.06.16.23291487Read

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.Semantic proximity Read

In vivo and ex vivo evidence for ketamine‐induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophreniaSemantic proximity Read

Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)Semantic proximity Read

Neurobiological mechanisms of ECT and TMS treatment in depression. Study protocol of a multimodal magnetic resonance investigationSemantic proximity Read

Ketamine induces synaptic and monoaminergic remodeling in human iPSC-derived neuronsSemantic proximity Read

Randomized trial, parallel-group to compare effect of low-intensity transcranial magnetic stimulation (Li-TMS) on sleep disorders, inflammation levels, and brain-derived neurotrophic factor in patients with depressionSemantic proximity Read

Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study.Semantic proximity Read

ACC Glu/GABA ratio is decreased in euthymic bipolar disorder I patients: possible in vivo neurometabolite explanation for mood stabilization.Semantic proximity Read

Kynurenines Increase MRS Metabolites in Basal Ganglia and Decrease Resting State Connectivity in Frontostriatal Reward Circuitry in DepressionSemantic proximity Read

Ultrasonic potentiation of ketamine neuromodulationSemantic proximity Read

Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actionsSemantic proximity Read

Transformations in Plasma Metabolic Profiles of Patients with Major Depression During Treatment: A Pilot Metabolomics StudySemantic proximity Read